October 06, 2015 –  Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. Among lung cancers, non-small cell lung …

Remarkable: Pembrolizumab (Keytruda) now also for advanced non-small cell lung cancer (NSCLC) Read more »

October 02, 2015 – Recently, the American Food and Drug Administration (FDA) approved Sacubitril/Valsartan (Entresto) for the treatment of heart failure. Similarly, a few days ago, the European Medicines Agency (EMA) recommended granting a marketing authorisation for Sacubitril/Valsartan (Entresto) for the treatment of adults with symptomatic chronic heart failure …

New medicine to treat heart failure: Sacubitril/Valsartan (Entresto) brings a new mechanism of action to the treatment of heart failure Read more »

 September 19, 2015 – The American Food and Drug Administration (FDA) just approved Cariprazine (Vraylar) capsules to treat schizophrenia and bipolar disorder in adults. Schizophrenia is a chronic, severe and disabling brain disorder affecting about one percent of Americans. Typically, …

Cariprazine (Vraylar): New treatment for schizophrenia and bipolar disorder approved Read more »

September 2, 2015 – The U.S. Food and Drug Administration approved Rodapitant (Varubi) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Rodapitant (Varubi) is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated …

Rodapitant (Varubi) approved as a new treatment for nausea and vomiting under chemotherapy Read more »

2. September 2015 – Die Amerikanische Food and Drug Administration (FDA) hat eben Rodapitant (Varubi) zugelassen. Rodapitant (Varubi)um soll Chemotherapie-induzierte Übelkeit und Erbrechen (Emesis) verhindern. Rodapitant (Varubi) wird bei Erwachsenen in Kombination mit anderen Arzneimitteln (Brechreizhemmenden Agentien) eingesetzt um die Übelkeit …

Rodapitant (Varubi) als neue Behandlung für Übelkeit und Erbrechen nach Chemotherapie zugelassen Read more »

September 06, 2015 – The American Food and Drug Administration just approved Uridine Triacetate (Xuriden), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 …

Uridine Triacetate (Xuriden), a new orphan drug approved to treat rare autosomal recessive disorder Read more »

September 01, 2015 – The American Food and Drug Administration recently approved Evolocumab (Repatha) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Evolocumab (Repatha), the second drug approved in a …

Evolocumab (Repatha) to treat certain patients with high cholesterol Read more »

August 29, 2015 – This may after all not be so good news for Type 2-Diabetes patients on DPP-4 inhibitor medications. The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines containing the pharmacologically active …

Drug Safety Communication: DPP-4 inhibitors for Type 2-Diabetes may cause severe joint pain Read more »

August 15, 2015 – Please find here the abstract of an recent article which is concerned with the genetic basis of smoking and the prospects of smoking cessation therapies in individual smokers.  The author of this blog thought it worthwhile …

Theragenomic Medicine: Where there is a cigarette, there is smoke. How much, that may be in your genes. Read more »

August 02, 2015 – The American Food and Drug Administration (FDA) very recently approved Sonidegib (Odomzo) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery …

Sonidegib (Odomzo): A second Hedgehog pathway inhibitor approved as new treatment for most common form of advanced skin cancer Read more »